Key result
GH treatment in idiopathic short stature mirrors GH deficiency metabolic responses without increasing diabetes risk.
Why the study?
Does recombinant human growth hormone treatment cause adverse metabolic outcomes in children with idiopathic short stature?
Systematic Review
Does recombinant human growth hormone treatment cause adverse metabolic outcomes in children with idiopathic short stature?
Growth hormone therapy in children with idiopathic short stature provides height gain without severe negative metabolic outcomes, similar to the metabolic response seen in children with GH deficiency.
Supports metabolic safety of GH in ISS; confirms comparable profile to GH deficiency without diabetes risk.
The US Food and Drug Administration approved use of recombinant human growth hormone (GH) for the treatment of idiopathic short stature (ISS) in children; however, few studies have evaluated metabolic outcomes. This article addresses whether children with ISS treated with GH experience the same metabolic benefits as children with GH deficiency (GHD) treated with GH. A systematic review of all published studies of GH treatment in children with ISS that included data on metabolic outcomes identified five studies. No meta-analysis has been performed.Studies show a metabolic response to GH treatment in children with ISS similar to that observed in children with GHD; effects include a transient decrease in insulin sensitivity and a dose-dependent increase in insulin-like growth factor I. However, no increase in the risk of diabetes was found. Children with ISS seem to benefit from GH treatment in terms of height gain without any severe negative metabolic outcomes.
No takes yet. Share an insight, caveat, or question.
Jovanna Dahlgren (2011) conducted a systematic review in Idiopathic short stature (ISS). Recombinant human growth hormone (GH) vs. Children with GH deficiency (GHD) treated with GH was evaluated on Metabolic outcomes. Growth hormone treatment in children with idiopathic short stature showed metabolic responses similar to those in GH deficiency, without severe negative metabolic outcomes or increased diabetes risk.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: